Vorasidenib: Difference between revisions
Content deleted Content added
added Category:Trifluoromethyl compounds using HotCat |
added Category:Triazines using HotCat |
||
| Line 106: | Line 106: | ||
[[Category:Pyridines]] |
[[Category:Pyridines]] |
||
[[Category:Trifluoromethyl compounds]] |
[[Category:Trifluoromethyl compounds]] |
||
[[Category:Triazines]] |
|||
Revision as of 00:59, 7 September 2023
 | |
| Clinical data | |
|---|---|
| License data |
|
| Drug class | Antineoplastic agent |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C14H13ClF6N6 |
| Molar mass | 414.74 g·mol−1 |
Vorasidenib is an anti-cancer medication for the treatment of low-grade Glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer. [1]In a phase-III-trial it was shown to prolong progression-free survival in patients with IDH1- or IDH2-Mutant Low-Grade Glioma.[2]
References
- ^ "Vorasidenib compound summary". pubchem. 2 September 2023. Retrieved 6 September 2023.
{{cite web}}: CS1 maint: url-status (link) - ^ Ingo K. Mellinghoff; et al. (2023-08-17), "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma", New England Journal of Medicine, vol. 389, no. 7, pp. 389–601, doi:10.1056/NEJMoa2304194, PMC 5900343, PMID 29670690
